- Home
- NAMI vs TRVI Comparison
NAMI vs TRVI Comparison
Compare NAMI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMI
- TRVI
- Stock Information
- Founded
- NAMI 2014
- TRVI 2011
- Country
- NAMI China
- TRVI United States
- Employees
- NAMI N/A
- TRVI N/A
- Industry
- NAMI
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NAMI
- TRVI Health Care
- Exchange
- NAMI NYSE
- TRVI Nasdaq
- Market Cap
- NAMI 286.0M
- TRVI 341.4M
- IPO Year
- NAMI 2024
- TRVI 2019
- Fundamental
- Price
- NAMI $3.79
- TRVI $3.76
- Analyst Decision
- NAMI
- TRVI Strong Buy
- Analyst Count
- NAMI 0
- TRVI 8
- Target Price
- NAMI N/A
- TRVI $9.31
- AVG Volume (30 Days)
- NAMI 104.9K
- TRVI 659.4K
- Earning Date
- NAMI 02-11-2025
- TRVI 11-06-2024
- Dividend Yield
- NAMI N/A
- TRVI N/A
- EPS Growth
- NAMI N/A
- TRVI N/A
- EPS
- NAMI 0.37
- TRVI N/A
- Revenue
- NAMI $56,127,097.00
- TRVI N/A
- Revenue This Year
- NAMI N/A
- TRVI N/A
- Revenue Next Year
- NAMI N/A
- TRVI N/A
- P/E Ratio
- NAMI $10.20
- TRVI N/A
- Revenue Growth
- NAMI 64.40
- TRVI N/A
- 52 Week Low
- NAMI $3.40
- TRVI $1.27
- 52 Week High
- NAMI $7.75
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- NAMI N/A
- TRVI 48.03
- Support Level
- NAMI N/A
- TRVI $3.63
- Resistance Level
- NAMI N/A
- TRVI $4.06
- Average True Range (ATR)
- NAMI 0.00
- TRVI 0.30
- MACD
- NAMI 0.00
- TRVI -0.09
- Stochastic Oscillator
- NAMI 0.00
- TRVI 12.21
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The Company generates revenue by selling its content to hardware manufacturers in China whereby they are allowed to install the Company's digital educational content on the manufacturers' devices for sale to end users.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.